New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 17, 2013
08:04 EDTALNYAlnylam announces proof-of-concept data from RNAi program
Alnylam announced that it has presented pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 for the treatment of porphyria including acute intermittent porphyria. "The new research results support the advancement of RNAi therapeutics as a promising strategy for the prevention and/or treatment of acute attacks in patients with AIP," the company said. It added, "In particular, a prototype GalNAc-siRNA targeting ALAS-1 was shown to be effective in blocking ALA and PBG production in both prophylactic and treatment models of AIP. The company is on track to designate a GalNAc-siRNA development candidate, ALN-AS1, in late 2013 resulting in an investigational new drug (IND) filing in 2014."
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
07:04 EDTALNYAlnylam receives orphan drug designation for revusiran
Subscribe for More Information
May 19, 2015
11:03 EDTALNYAlnylam transthyretin amyloidosis treatment designated for FDA orphan status
Alnylam's revusiran was designated by the FDA for orphan drug status as a treatment of transthyretin amyloidosis. Reference Link
07:28 EDTALNYUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
May 17, 2015
15:24 EDTALNYAlnylam files ALN-AAT trial application, reports positive results in primates
Subscribe for More Information
May 12, 2015
07:52 EDTALNYLeerink to hold a tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use